Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 91Neoplasm Metastasis 7Prostatic Neoplasms, Castration-Resistant 5Breast Neoplasms 3Neoplasms 2Castration-resistant Prostate Cancer 2Urinary Bladder Neoplasms 1Stage II Prostate Adenocarcinoma 1Salivary Glands Tumors 1Prostate Cancer Metastatic 1Prostate Adenocarcinoma 1Oligometastatic Prostate Carcinoma 1Newly Diagnosed Oligometastatic Prostate Cancer 1Neoadjuvant Therapy 1NSCLC Harboring NRG1 Fusion 1Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-Resistant Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer 1Hyperaldosteronism 1Cushing Syndrome 1Carcinoma, Transitional Cell 1Adrenocortical Carcinoma 1Adenocarcinoma 1

Interventions

enzalutamide 3Abiraterone Acetate 2testosterone enanthate 1pembrolizumab 1disitamab vedotin 1abiraterone 1Radium-223 1Prednisone 1Ketoconazole 1Hydrocortisone 1Flutamide 1Calcitriol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Castration-resistant Prostate Cancer × Abiraterone Acetate × Clear all
NCT02025010 2025-04-15

Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
60 enrolled 17 charts
Genitourinary

Castration-resistant Prostate Cancer

NCT02429193 2020-01-13

BARRIER-P

University Health Network, Toronto

Phase 2 Completed
16 enrolled
Genitourinary

Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡